Research
Hormonal
Semaglutide reduces cardiovascular risk (MACE) and improves lipid profiles and blood pressure in patients with type 2 diabetes, independent of weight loss.
For patients with Type 2 Diabetes and high cardiovascular risk, semaglutide offers significant protection against major adverse cardiovascular events (heart attack, stroke, cardiovascular death) and slows kidney disease progression. It also modestly lowers blood pressure and improves lipid profiles through mechanisms independent of weight loss.
GoodSupportsHIGH confidence
Semaglutide ha ridotto significativamente sia l’incidenza di MACE... che il tasso di progressione o nuova insorgenza di nefropatia... riduce i livelli di pressione arteriosa... indipendenti dalla perdita di peso
Why this rating
Based on large RCTs (SUSTAIN 6, PIONEER 6) showing non-inferiority/superiority for MACE.
Source
Semaglutide
Agostino Milluzzo et al. · L Endocrinologo · 2022
DOI 10.1007/s40619-022-01061-0
narrative_reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide (subcutaneous 1 mg/week and oral 14 mg/day) significantly reduces HbA1c and body weight in patients with type 2 diabetes, with subcutaneous administration showing superior efficacy compared to other GLP-1 receptor agonists.Good
- Semaglutide use in patients with pre-existing retinopathy is associated with an increased risk of retinal complications, likely due to rapid glycemic improvement, requiring cautious use.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →